Jacob N Hunnicutt1, Anne L Hume2, Christine M Ulbricht1, Jennifer Tjia1, Kate L Lapane1. 1. Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA. 2. Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Abstract
PURPOSE: To estimate the proportion of residents newly initiating long-acting opioids in comparison to residents initiating short-acting opioids and examine variation in long-acting opioid initiation by region and resident characteristics. METHODS: This cross-sectional study included 182 735 long-stay nursing home residents in 13 881 US nursing homes who were Medicare beneficiaries during 2011 to 2013 and initiated a short-acting or long-acting opioid (excluding residents <50 years old, those with cancer, or receiving hospice care). Medicare Part D prescription claims were used to identify residents as newly initiating short-acting or long-acting opioids, defined as having a prescription claim for an opioid with no prior opioid prescriptions in the preceding 60 days. We estimated the overall proportion of initiators prescribed long-acting opioids. Regional variation was examined by mapping results by state and hospital referral regions. Logistic models were used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). RESULTS: Two percent of opioid initiators were prescribed long-acting opioids. State variation in long-acting opioid initiation ranged from 0.6% to 7.5% (5th-95th percentiles: 0.6-6.4%). Resident characteristics associated with increased long-acting opioid initiation included severe physical limitations (vs none/mild limitations; aOR: 2.13, 95% CI: 1.92-2.37) and pain (staff-assessed vs no pain; aOR: 1.59 95% CI: 1.40-1.80), whereas being non-White was inversely associated (non-Hispanic black vs non-Hispanic white; aOR: 0.70, 95% CI: 0.62-0.79). CONCLUSION: United States nursing home residents predominantly initiate short-acting opioids in accordance with Center for Disease Control and Prevention guidelines. Documented variation by geographic and resident characteristics suggests that improvements are possible.
PURPOSE: To estimate the proportion of residents newly initiating long-acting opioids in comparison to residents initiating short-acting opioids and examine variation in long-acting opioid initiation by region and resident characteristics. METHODS: This cross-sectional study included 182 735 long-stay nursing home residents in 13 881 US nursing homes who were Medicare beneficiaries during 2011 to 2013 and initiated a short-acting or long-acting opioid (excluding residents <50 years old, those with cancer, or receiving hospice care). Medicare Part D prescription claims were used to identify residents as newly initiating short-acting or long-acting opioids, defined as having a prescription claim for an opioid with no prior opioid prescriptions in the preceding 60 days. We estimated the overall proportion of initiators prescribed long-acting opioids. Regional variation was examined by mapping results by state and hospital referral regions. Logistic models were used to estimate adjusted odds ratios (aORs) and 95% confidence intervals (CIs). RESULTS: Two percent of opioid initiators were prescribed long-acting opioids. State variation in long-acting opioid initiation ranged from 0.6% to 7.5% (5th-95th percentiles: 0.6-6.4%). Resident characteristics associated with increased long-acting opioid initiation included severe physical limitations (vs none/mild limitations; aOR: 2.13, 95% CI: 1.92-2.37) and pain (staff-assessed vs no pain; aOR: 1.59 95% CI: 1.40-1.80), whereas being non-White was inversely associated (non-Hispanic black vs non-Hispanic white; aOR: 0.70, 95% CI: 0.62-0.79). CONCLUSION: United States nursing home residents predominantly initiate short-acting opioids in accordance with Center for Disease Control and Prevention guidelines. Documented variation by geographic and resident characteristics suggests that improvements are possible.
Authors: Camilla B Pimentel; Jerry H Gurwitz; Jennifer Tjia; Anne L Hume; Kate L Lapane Journal: J Am Geriatr Soc Date: 2016-08-03 Impact factor: 5.562
Authors: R Bernabei; G Gambassi; K Lapane; F Landi; C Gatsonis; R Dunlop; L Lipsitz; K Steel; V Mor Journal: JAMA Date: 1998-06-17 Impact factor: 56.272
Authors: Aida B Won; Kate L Lapane; Sue Vallow; Jeff Schein; John N Morris; Lewis A Lipsitz Journal: J Am Geriatr Soc Date: 2004-06 Impact factor: 5.562
Authors: Jacob N Hunnicutt; Anne L Hume; Shao-Hsien Liu; Christine M Ulbricht; Jennifer Tjia; Kate L Lapane Journal: Drugs Aging Date: 2018-10 Impact factor: 3.923
Authors: Marjolein J M Vranken; Marie-Hélène D B Schutjens; Aukje K Mantel-Teeuwisse Journal: Pharmacoepidemiol Drug Saf Date: 2019-01 Impact factor: 2.890
Authors: Anita Iacono; Michael A Campitelli; Susan E Bronskill; David B Hogan; Andrea Iaboni; Laura C Maclagan; Tara Gomes; Mina Tadrous; Charity Evans; Andrea Gruneir; Qi Guan; Thomas Hadjistavropoulos; Cecilia Cotton; Sudeep S Gill; Dallas P Seitz; Joanne Ho; Colleen J Maxwell Journal: Drugs Aging Date: 2022-08-17 Impact factor: 4.271